ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Evaxion Biotech AS

Evaxion Biotech AS (EVAX)

1.06
0.214
(25.30%)
Closed December 28 4:00PM
1.08
0.02
(1.89%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.08
Bid
1.06
Ask
1.08
Volume
8,528,485
0.89 Day's Range 1.22
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.846
Open
1.21
Last Trade Time
Financial Volume
$ 8,666,865
VWAP
1.0162
Average Volume (3m)
-
Shares Outstanding
5,580,000
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
507k
Net Profit
-152.41M

About Evaxion Biotech AS

Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise, and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in... Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise, and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Its two lead product candidates are EVX-01 and EVX-02, for the treatment of various cancers. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Horsholm, Dnk
Founded
-
Evaxion Biotech AS is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EVAX. The last closing price for Evaxion Biotech AS was $0.85. Over the last year, Evaxion Biotech AS shares have traded in a share price range of $ 0.00 to $ 0.00.

Evaxion Biotech AS currently has 5,580,000 shares outstanding. The market capitalization of Evaxion Biotech AS is $4.72 million.

EVAX Latest News

Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity

Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7 million loan with EIB into an equity-type instrumentSuch conversion...

Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...

Evaxion announces 2025 milestones reflecting continued strong strategy execution

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones reflect all parts of Evaxion’s strategy for value...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

EVAX - Frequently Asked Questions (FAQ)

What is the current Evaxion Biotech AS share price?
The current share price of Evaxion Biotech AS is $ 1.08
How many Evaxion Biotech AS shares are in issue?
Evaxion Biotech AS has 5,580,000 shares in issue
What is the market cap of Evaxion Biotech AS?
The market capitalisation of Evaxion Biotech AS is USD 4.72M
What is the 1 year trading range for Evaxion Biotech AS share price?
Evaxion Biotech AS has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the reporting currency for Evaxion Biotech AS?
Evaxion Biotech AS reports financial results in USD
What is the latest annual turnover for Evaxion Biotech AS?
The latest annual turnover of Evaxion Biotech AS is USD 507k
What is the latest annual profit for Evaxion Biotech AS?
The latest annual profit of Evaxion Biotech AS is USD -152.41M
What is the registered address of Evaxion Biotech AS?
The registered address for Evaxion Biotech AS is DR. NEERGAARDS VEJ 5F, HORSHOLM, 2970
What is the Evaxion Biotech AS website address?
The website address for Evaxion Biotech AS is www.evaxion-biotech.com
Which industry sector does Evaxion Biotech AS operate in?
Evaxion Biotech AS operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INTZIntrusion Inc
$ 2.167
(381.56%)
189.59M
AILEiLearningEngines Inc
$ 0.5932
(267.31%)
563.26M
HUBCWHub Cyber Security Ltd
$ 0.035
(250.00%)
2.79M
GTIGraphjet Technology
$ 0.967551
(185.83%)
398.95M
LITMSnow Lake Resources Ltd
$ 1.61
(82.95%)
131.98M
NEUPNeuphoria Therapeutics Inc
$ 4.11
(-92.30%)
940.73k
VIRXViracta Therapeutics Inc
$ 0.16
(-32.49%)
9.47M
PRFXPainReform Ltd
$ 3.48
(-28.98%)
949.52k
AIREreAlpha Tech Corporation
$ 2.56
(-28.49%)
8.42M
AVGRAvinger Inc
$ 0.9721
(-24.05%)
2.16M
AILEiLearningEngines Inc
$ 0.5932
(267.31%)
563.26M
GTIGraphjet Technology
$ 0.967551
(185.83%)
398.95M
RGTIRigetti Computing Inc
$ 17.08
(10.62%)
305.79M
XTIAXTI Aerospace Inc
$ 0.03935
(-1.63%)
268M
QSIQuantum Si Inc
$ 3.585
(66.74%)
256.01M

EVAX Discussion

View Posts
glenn1919 glenn1919 1 day ago
evax.....................https://stockcharts.com/h-sc/ui?s=evax&p=W&b=5&g=0&id=p86431144783
👍️0
subslover subslover 2 days ago
PROXY out https://www.otcmarkets.com/filing/html?id=18071025&guid=lKY-kHdxdv3Th3h
👍️0
subslover subslover 2 days ago
Was once a high-flying ticket.
👍️0
glenn1919 glenn1919 2 days ago
EVAX....................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 days ago
$2.04 + 120% looks good $14 looked best lol
👍️0
tw0122 tw0122 2 days ago
$1.90
👍️0
tw0122 tw0122 2 days ago
Hot off the presses $1.64 + 83%
👍️0
glenn1919 glenn1919 1 month ago
EVAX.....................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
EVAX under $3
👍️0
Monksdream Monksdream 5 months ago
EVAX under $3
👍️0
Monksdream Monksdream 5 months ago
EVAX under $3
👍️0
Monksdream Monksdream 6 months ago
EVAX under $5
👍️0
Monksdream Monksdream 7 months ago
EVAX under $5
👍️0
Monksdream Monksdream 10 months ago
EVAX new 52 week low
👍️0
Awl416 Awl416 10 months ago
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
👍️0
BooDog BooDog 11 months ago
Halted. Offering exercise @ $4???? no way, that'll get reoffered for lower imo.

https://www.globenewswire.com/news-release/2024/02/01/2822093/0/en/Evaxion-Biotech-Announces-Pricing-of-15-Million-Public-Offering.html
👍️0
da_stock_analyst da_stock_analyst 11 months ago
#EVAX 🔥 low float crazy stock! Can run big tomorrow! $evax
👍️0
subslover subslover 11 months ago
Thanks! 14.77 is INSANITY! Hey, look what is going on with AFIB. No news since November. I used to trade that one in the past and banked several times
👍️0
TheFinalCD TheFinalCD 11 months ago
nice trading, you got ,more than me

this POS hit 14.77 ah

got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))
👍️0
Awl416 Awl416 11 months ago
LOL
👍️0
rdeano221 rdeano221 11 months ago
$EVAX Jan. 24, 2024, 07:32 AM
InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Evaxion Biotech (NASDAQ:EVAX) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE:MRK).

A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech. That comes from the 2,297,884 shares of EVAX and warrants to acquire another 2,297,704 shares that the company owns.

The stake that Merck holds is based on the 40,204,700 shares outstanding as of Jan. 11, 2024. That comes from 37,906,996 shares of MRK stock outstanding and 2,297,704 shares issuable upon the exercise of warrants.
👍️0
subslover subslover 11 months ago
It's amazing what a couple of keywords can do! Excellent IR work. I got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))
👍️0
TheFinalCD TheFinalCD 11 months ago
$13'S ON THAT NEWS, POST RS PLAYS CAN BE WILD

I BOUGHT AS LOW AS 7.77 BUY DIDNT HOLD


WHERE DID YOU SELL?

Message in reply to:
LOL. Looks fake but I'll take it, man! :)
👍️0
subslover subslover 11 months ago
$11.93 and halted again
👍️0
TheFinalCD TheFinalCD 11 months ago
OF COURSE 9.72 HALTED UP

OPEN $10+
👍️0
subslover subslover 11 months ago
Hey! its all about making $$$$ :)
👍️0
TheFinalCD TheFinalCD 11 months ago
9.50 WAS MY HIGHEST SELL

NOW 8.50
👍️0
TheFinalCD TheFinalCD 11 months ago
I SEE IT NOW... 1-10 RS

WHAT HAPPENED ON THE 22ND FOR EVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44
👍️0
TheFinalCD TheFinalCD 11 months ago
WHAT HAPPENED ON THE 22ND FOR NVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44
👍️0
TheFinalCD TheFinalCD 11 months ago
;LOOKS LIKE $10+ COMING SOON
👍️0
subslover subslover 11 months ago
Yeah, but well-written fluff. Took a position last night,not gonna hold it long
👍️0
TheFinalCD TheFinalCD 11 months ago
EVAX 8.88 you mean fluff?
👍️0
subslover subslover 11 months ago
LOL. Looks fake but I'll take it, man! :)
👍️0
subslover subslover 11 months ago
LOL. Looks fake but I'll take it, man! :)
👍️0
TheFinalCD TheFinalCD 11 months ago
EVAX 7.77 Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html

https://finviz.com/quote.ashx?t=EVAX&p=d#google_vignette
👍️0
Awl416 Awl416 11 months ago
LOL

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
👍️0
subslover subslover 11 months ago
NEWS
Evaxion Announces Completion of ADS Ratio Change
COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change became effective on January 22, 2024 (the “Effective Date”).

For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company’s ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement. The exchange of one (1) new ADS for every ten (10) then-held (existing) ADSs occurred automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by The Bank of New York Mellon, the depositary bank (the “Depositary”). Registered holders of the Company’s ADSs held in certificated form were required on a mandatory basis to surrender their certificated ADSs to the Depositary for cancellation and received one (1) new ADS in exchange for every ten (10) existing ADSs then-held. Holders of uncertificated ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) had their ADSs cancelled and automatically exchanged, receiving one (1) new ADS for every ten (10) existing ADS then-held. The Company’s ADSs continue to be traded on The Nasdaq Capital Market under the ticker symbol “EVAX”.

The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s equity, except to the extent that the ratio change would have resulted in a shareholder owning fractional ADSs. No fractional new ADSs were issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary.

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company’s ADSs.
👍️0
Awl416 Awl416 11 months ago
Some would say unnecessary move AH

Of course they just did a RS too
👍️0
Disquisition Disquisition 11 months ago
INDESCRIBABLE DUMPING
👍️0
Renee Renee 12 months ago
EVAX: planned one for 10 reverse split for Jan. 22,2024:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
BooDog BooDog 1 year ago
Today's range $0.57 - $0.77
👍️0
BooDog BooDog 1 year ago
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies

COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

https://ih.advfn.com/stock-market/NASDAQ/evaxion-biotech-as-EVAX/stock-news/92667300/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
BooDog BooDog 1 year ago
NEWS: Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023 11:15 ET
| Source: Evaxion Biotech


https://www.globenewswire.com/news-release/2023/10/31/2770437/0/en/Evaxion-Announces-Encouraging-Initial-Phase-2-Clinical-Data-on-Its-Personalized-Cancer-Vaccine-EVX-01.html
👍️0
BooDog BooDog 1 year ago
High $1.10.
👍️0
BooDog BooDog 1 year ago
Maybe this time the push actually happens!!
👍️0
BooDog BooDog 1 year ago
May be a push coming.

https://ih.advfn.com/stock-market/NASDAQ/evaxion-biotech-as-EVAX/stock-news/92119783/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
BooDog BooDog 1 year ago
$EVAX $ WOULD BE EXCELLENT!
👍️0
BooDog BooDog 1 year ago
Probably end up on the OTC imo. They're bleeding themselves and must realize it by now. I'm not sure they can do a RS and maintain compliance without some serious funding. Which will likely be toxic.

just my guess. But, it can still be playable with the volatility.

All on thge ask @ .48...

0.48
132700
batx
0.48
132700
edgx
0.48
132700
NSDQ
0.48
132700
arcx

Crazy. Shorts are certainly taking advantage.

IMO
👍️0
Monksdream Monksdream 1 year ago
EVAX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
Reverse split candidate or banishment to the OTC
👍️0

Your Recent History

Delayed Upgrade Clock